Answer
Mepolizumab (Nucala) has not been studied in patients with organ-threatening or life-threatening manifestations of eosinophilic granulomatosis with polyangiitis (EGPA).
Sources for this answer
- Nucala 100 mg solution for injection in pre-filled penGlaxoSmithKline UK · emc · SmPC §4.4 Special warnings and precautions for use · Version 11Document updated
Sources checked